F9 and hemophilia B: A single intravenous infusion of HEMGENIX leads to cell transduction and an increase in circulating factor IX activity in patients with hemophilia B. This therapy has shown significant potential in providing long-term benefits for adult patients with hemophilia B [197,198,199].